{"id":96892,"date":"2025-08-25T22:29:08","date_gmt":"2025-08-25T22:29:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/96892\/"},"modified":"2025-08-25T22:29:08","modified_gmt":"2025-08-25T22:29:08","slug":"heres-why-greenskeeper-asset-management-added-novo-nordisk-nvo-to-its-portfolio","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/96892\/","title":{"rendered":"Here\u2019s Why GreensKeeper Asset Management Added Novo Nordisk (NVO) to Its Portfolio"},"content":{"rendered":"\n

GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here<\/a>. The Value Fund has reached the midpoint of 2025, recording a decline of -3.6% net of fees and expenses. The US dollar has experienced a substantial depreciation, negatively impacting performance by over 5.0% year-to-date (YTD). The fund\u2019s robust beginning in Q1 was reversed in Q2 as markets shrugged off President Trump\u2019s \u201cLiberation Day\u201d tariffs and adopted a full \u201crisk on\u201d stance. In addition, you can check the fund\u2019s top 5 holdings to determine its best picks for 2025.<\/p>\n

In its second-quarter 2025 investor letter, GreensKeeper Asset Management highlighted stocks such as Novo Nordisk A\/S (NYSE:NVO<\/a>). Novo Nordisk A\/S (NYSE:NVO) engages in the research and development, manufacture, and distribution of pharmaceutical products. The one-month return of Novo Nordisk A\/S (NYSE:NVO) was -17.42%, and its shares lost 57.89% of their value over the last 52 weeks. On August 22, 2025, Novo Nordisk A\/S (NYSE:NVO) stock closed at $56.98 per share, with a market capitalization of $246.974 billion.<\/p>\n

Burke Wealth Management stated the following regarding Novo Nordisk A\/S (NYSE:NVO) in its second quarter 2025 investor letter:<\/p>\n

“We made one new purchase in the quarter: Novo Nordisk A\/S (NYSE:NVO), which we have owned previously. NVO, a Danish pharmaceutical company, is the world\u2019s leading insulin maker. But today the company\u2019s growth is driven by its GLP-1 franchise, which comprises Ozempic, Wegovy and Rybelsus. The stock has come under pressure following the uptake of competitor Eli Lilly\u2019s (LLY) GLP-1 products Mounjaro and Zepbound. LLY will likely continue to gain share, but we believe the market for GLP-1s is large enough for both companies to continue increasing their revenues, and that the market is undervaluing NVO\u2019s GLP-1 pipeline.”<\/p>\n

\"Novo Novo Nordisk A\/S (NVO): “Canada’s A Backdoor,” Says Jim Cramer <\/p>\n

An elderly couple receiving insulin from a pharmacist, representing healthcare company’s successful pharmaceutical products.<\/p>\n

Novo Nordisk A\/S (NYSE:NVO) is not on our list of\u00a030 Most Popular Stocks Among Hedge Funds<\/a>. As per our database, 45 hedge fund portfolios held Novo Nordisk A\/S (NYSE:NVO) at the end of the second quarter, which was 60 in the previous quarter. While we acknowledge the potential of Novo Nordisk A\/S (NYSE:NVO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock<\/a>.<\/p>\n

Story Continues <\/p>\n","protected":false},"excerpt":{"rendered":"GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter…\n","protected":false},"author":2,"featured_media":96893,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[45,49,48,133,56481,27809,27810,5246,131,132,56480],"class_list":["post-96892","post","type-post","status-publish","format-standard","has-post-thumbnail","category-personal-finance","tag-business","tag-ca","tag-canada","tag-finance","tag-greenskeeper","tag-investment-management-company","tag-investor-letter","tag-novo-nordisk","tag-personal-finance","tag-personalfinance","tag-pharmaceutical-products"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/96892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=96892"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/96892\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/96893"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=96892"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=96892"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=96892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}